Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price shot up 15.4% on Wednesday . The stock traded as high as C$0.24 and last traded at C$0.23. 382,000 shares changed hands during trading, a decline of 37% from the average session volume of 601,939 shares. The stock had previously closed at C$0.20.
Hemostemix Stock Performance
The firm has a market capitalization of C$27.01 million, a P/E ratio of -15.50 and a beta of 0.20. The company has a 50-day simple moving average of C$0.10 and a two-hundred day simple moving average of C$0.08.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- AI Demand Sparks Opportunities for These 3 Nuclear Energy Leaders
- 3 Small Caps With Big Return Potential
- TSMC: Long-Term Outlook Still Strong as Geopolitical Risk Rises
- Retail Stocks Investing, Explained
- Uber’s NVIDIA Deal and Buybacks Signal Major Upside
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
